Prometheus Biosciences Inc.

Industry

  • Pharmaceuticals
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Large Molecule
      • Antibodies
    • Drug Discovery Technologies
      • Bioinformatics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
See more in Biomedtracker

Latest on Prometheus Biosciences Inc.

Scrip

Teva/Sanofi’s Phase IIb Data In IBD Look Competitive Vs. Merck, Roche

 
• By Joseph Haas

Teva and Sanofi unveiled positive Phase IIb data on 17 December for the TL1A-targeting antibody candidate they are developing to compete against candidates from the same class at Roche and Merck &

Scrip

AbbVie Adds IBD Candidate In Deal With China’s FutureGen

 
• By Joseph Haas

Who: AbbVie/FutureGen What: AbbVie has licensed global development and commercialization rights to a preclinical TL1A-targeting antibody for development in inflammatory bowel disease (IBD) from Fut

Scrip

Merck Points To Antibody-Drug Conjugate Potential During Another Growth Quarter

 
• By Joseph Haas

Merck & Co., Inc. reported strong Q3 financials including continued growth for Keytruda on 26 October, but much of the focus during its earnings call centered on the recent collaboration with Daiich

Scrip

Roivant/Roche: Did Pfizer Miss Out?

 
• By Jessica Merrill

The original deal between Pfizer Inc. and Roivant Sciences Ltd. for the tumor necrosis factor-like ligand 1A (TL1A) inhibitor RVT-3101 was perplexing when it happened in December 2022, because Pfi